Get the Stockscreener App
1.51
1.31%
-0.02
After Hours:
1.46
-0.05
-3.31%
Gri Bio Inc stock is traded at $1.51, with a volume of 147.70K.
It is down -1.31% in the last 24 hours and down -73.13% over the past month.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
See More
Previous Close:
$1.53
Open:
$1.5
24h Volume:
147.70K
Relative Volume:
0.51
Market Cap:
$1.10M
Revenue:
-
Net Income/Loss:
$-8.26M
P/E Ratio:
-0.0282
EPS:
-53.609
Net Cash Flow:
$-12.17M
1W Performance:
+24.79%
1M Performance:
-73.13%
6M Performance:
-81.84%
1Y Performance:
-98.66%
1-Day Range:
$1.4204
$1.5899
1-Week Range:
$1.16
$1.98
52-Week Range:
$1.10
$130.39
Gri Bio Inc Stock (GRI) Company Profile
Name
Gri Bio Inc
Sector
Industry
Phone
(619) 400-1171
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA
Compare GRI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
1.51 | 1.10M | 0 | -8.26M | -12.17M | -53.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | H.C. Wainwright | Buy |
Gri Bio Inc Stock (GRI) Latest News
FY2025 Earnings Forecast for GRI Bio Issued By HC Wainwright - Defense World
GRI Bio appoints Withum as new accounting firm By Investing.com - Investing.com Canada
GRI Bio Announces Abstract Selected for Poster Discussion - GlobeNewswire
Major Scientific Breakthrough: GRI Bio's Novel Pulmonary Fibrosis Treatment Shows Promise - Stock Titan
GRI Bio appoints Withum as new accounting firm - Investing.com
GRI Bio (NASDAQ:GRI) Given Buy Rating at HC Wainwright - Defense World
H.C. Wainwright maintains Buy on GRI Bio stock, $10 target - Investing.com
H.C. Wainwright maintains Buy on GRI Bio stock, $10 target By Investing.com - Investing.com India
GRI stock touches 52-week low at $1.2 amid market fluctuations - Investing.com
GRI Bio regains compliance with Nasdaq’s minimum bid price rule - MSN
GRI Stock Down on Public Offering Despite Encouraging IPF Study Data - MSN
Gri Bio Announces Closing Of $5.0 Million Public Offering - MarketScreener
GRI Bio Announces Closing of $5.0 Million Public Offering - GlobeNewswire
GRI Bio Raises $5M, Eyes $18.3M Total Potential for Breakthrough Autoimmune Treatment - Stock Titan
GRI Stock Down On Public Offering Despite Encouraging IPF Study Data - Barchart.com
GRI Bio Shares Rebound In After-Hours Trading - Stocks Telegraph
GRI Bio (GRI) Reports Positive Interim Safety Results for IPF Tr - GuruFocus
Street can a-GRI on phase IIb safety win in IPF with tazarotene - BioWorld MedTech
GRI Bio Announces $5 Million Public Offering Amid Market Decline - Nasdaq
GRI Bio Prices up to $13 Million Equity Offering - MarketScreener
GRI Bio announces $5 million public offering - Investing.com
GRI Bio announces $5 million public offering By Investing.com - Investing.com Australia
GRI Bio Announces Pricing of $5.0 Million Public Offering - GlobeNewswire
GRI Bio Secures $5M Funding Deal: Warrants Could Add $13.3M More - Stock Titan
Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?GRI Bio (NASDAQ:GRI) - Benzinga
GRI Bio’s IPF drug shows promise in early trial By Investing.com - Investing.com South Africa
GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF - The Manila Times
GRI Bio reports interim 2-week safety results from Phase 2a study of GRI-0621 - TipRanks
GRI Bio’s IPF drug shows promise in early trial - Investing.com
Gri Bio IncIDMC Recommends Continuation Of Study With No Safety Concerns - MarketScreener
GRI Bio Reports Encouraging Interim 2-Week Safety Results - GlobeNewswire
Clinical Trial Breakthrough: GRI-0621 Clears Key Safety Milestone for IPF Treatment - Stock Titan
GRI Bio secures global patents for NKT cell modulators By Investing.com - Investing.com South Africa
GRI Bio secures global patents for NKT cell modulators - Investing.com
GRI Bio announces the granting of two global patents for Europe, Japan - TipRanks
GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan - GlobeNewswire
Global Patent Victory: GRI Bio's Breakthrough NKT Cell Treatment for Autoimmune Disease Gets Dual Approval - Stock Titan
Vallon Pharmaceuticals stock plunges to 52-week low of $4.95 By Investing.com - Investing.com South Africa
Vallon Pharmaceuticals stock plunges to 52-week low of $4.95 - Investing.com India
GRI Bio (GRI) to Release Quarterly Earnings on Thursday - Defense World
GRI Bio Participates in a Virtual Investor CEO Connect Segment - The Manila Times
GRI Bio's Breakthrough IPF Drug Shows Promise, Key Data Coming Next Quarter - StockTitan
GRI Bio expects cash to fund operations into Q2 of 2025 - TipRanks
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
GRI stock touches 52-week low at $5.12 amid market fluctuations - Investing.com
GRI Bio, Inc. Anticipates Key Phase 2a Data Readouts for GRI-0621 in 2025 While Securing Cash Runway for Operations - Nasdaq
GRI Bio Reports Full Year 2024 Financial Results and - GlobeNewswire
GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) - Yahoo
GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ('IPF”) - The Manila Times
GRI Bio, Inc. SEC 10-K Report - TradingView
GRI Bio regains compliance with Nasdaq minimum bid rule By Investing.com - Investing.com Australia
Gri Bio Inc Stock (GRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):